Tecartus
Brexucabtagene autoleucel
Lymphoma, Mantle-Cell
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanAuthorised
Holoclar
ex vivo expanded autologous human corneal epithelial cells containing stem cells
Stem Cell Transplantation
Corneal Diseases
Date of authorisation:
Revision: 11
Last updated:
MedicineHumanAuthorised
Strimvelis
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence
Severe Combined Immunodeficiency
Date of authorisation:
Revision: 10
Last updated:
MedicineHumanAuthorised
Abecma
idecabtagene vicleucel
Multiple Myeloma
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanAuthorised
Zolgensma
onasemnogene abeparvovec
Muscular Atrophy, Spinal
Date of authorisation:
Revision: 15
Last updated:
MedicineHumanAuthorised
Upstaza
eladocagene exuparvovec
Amino Acid Metabolism, Inborn Errors
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanAuthorised
Health technology assessment bodies

The European Medicines Agency (EMA) is working closely with health technology assessment (HTA) bodies. Regional and national HTA bodies provide recommendations on medicines and other health technologies that can be financed or reimbursed by the healthcare system in a particular European Union (EU) Member State or region.

Last updated:
HumanAdvanced therapies